1. Home
  2. SONY vs VRTX Comparison

SONY vs VRTX Comparison

Compare SONY & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sony Group Corporation

SONY

Sony Group Corporation

HOLD

Current Price

$24.21

Market Cap

127.6B

ML Signal

HOLD

Logo Vertex Pharmaceuticals Incorporated

VRTX

Vertex Pharmaceuticals Incorporated

HOLD

Current Price

$547.81

Market Cap

123.4B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
SONY
VRTX
Founded
1946
1989
Country
Japan
United States
Employees
N/A
N/A
Industry
Consumer Electronics/Appliances
EDP Services
Sector
Consumer Staples
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
127.6B
123.4B
IPO Year
1996
2006

Fundamental Metrics

Financial Performance
Metric
SONY
VRTX
Price
$24.21
$547.81
Analyst Decision
Hold
Buy
Analyst Count
1
29
Target Price
$22.00
$539.69
AVG Volume (30 Days)
5.5M
1.3M
Earning Date
05-13-2026
05-04-2026
Dividend Yield
5.33%
N/A
EPS Growth
N/A
836.54
EPS
N/A
8.33
Revenue
N/A
$2,488,652,000.00
Revenue This Year
N/A
$10.79
Revenue Next Year
$3.08
$10.47
P/E Ratio
N/A
$65.79
Revenue Growth
N/A
46.20
52 Week Low
$19.32
$374.17
52 Week High
$30.34
$555.32

Technical Indicators

Market Signals
Indicator
SONY
VRTX
Relative Strength Index (RSI) 64.70 64.11
Support Level $20.64 $458.05
Resistance Level $24.67 N/A
Average True Range (ATR) 0.30 14.06
MACD -0.01 3.82
Stochastic Oscillator 78.19 83.09

Price Performance

Historical Comparison
SONY
VRTX

About SONY Sony Group Corporation

Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is the global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with five major business segments.

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Share on Social Networks: